Johnson & Johnson (JNJ)vsNational HealthCare Corporation (NHC)
JNJ
Johnson & Johnson
$265.58
-0.29%
HEALTHCARE · Cap: $640.02B
NHC
National HealthCare Corporation
$224.47
-0.20%
HEALTHCARE · Cap: $3.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 6181% more annual revenue ($97.93B vs $1.56B). JNJ leads profitability with a 21.5% profit margin vs 9.0%. NHC appears more attractively valued with a PEG of 0.82. NHC earns a higher WallStSmart Score of 61/100 (C+).
JNJ
Buy59
out of 100
Grade: C
NHC
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$265.58
$125.01 premium
Margin of Safety
-65.7%
Fair Value
$101.60
Current Price
$224.47
$122.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Earnings expanding 67.1% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : NHC
The strongest argument for NHC centers on EPS Growth, Debt/Equity, Altman Z-Score. PEG of 0.82 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : NHC
No major red flags identified for NHC, but monitor valuation.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NHC is a value play — different risk/reward profiles.
NHC carries more volatility with a beta of 0.63 — expect wider price swings.
NHC is growing revenue faster at 8.8% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
NHC scores higher overall (61/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →National HealthCare Corporation
HEALTHCARE · MEDICAL CARE FACILITIES · USA
National HealthCare Corporation operates, manages, and provides services to skilled nursing facilities, assisted living facilities, independent living facilities, home health programs, and a behavioral health hospital. The company is headquartered in Murfreesboro, Tennessee.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?